CAR treatment, toxicity, and response of patients with B-ALL
| n (%) . | Overall (n = 139) . | Overweight/obese (n = 41) . | Hispanic (n = 40) . | Other non-Hispanic (n = 22) . |
|---|---|---|---|---|
| CAR construct | ||||
| CD19 | 50 (36.0) | 15 (36.6) | 18 (45.0) | 7 (31.8) |
| CD22 | 71 (51.1) | 19 (46.3) | 15 (37.5) | 12 (54.5) |
| CD19/22 | 18 (12.9) | 7 (17.1) | 7 (17.5) | 3 (13.6) |
| CRS ASTCT grade | ||||
| None | 33 (23.7) | 10 (24.4) | 12 (30.0) | 6 (27.3) |
| 1 | 47 (33.8) | 17 (41.5) | 9 (22.5) | 6 (27.3) |
| 2 | 34 (24.5) | 7 (17.1) | 7 (17.5) | 6 (27.3) |
| 3 | 20 (14.4) | 6 (14.6) | 10 (25.0) | 3 (13.6) |
| 4 | 5 (3.6)∗ | 1 (2.4) | 2 (5.0) | 1 (4.5) |
| Developed neurotoxicity | 29 (20.9) | 8 (19.5) | 9 (22.5) | 2 (9.1) |
| CR | ||||
| Yes | 94 (67.6) | 26 (63.4) | 25 (62.5) | 14 (63.6) |
| No | 44 (31.7) | 15 (36.6) | 15 (37.5) | 7 (31.8) |
| Not evaluable | 1 (0.7)∗ | 0 | 0 | 1 (4.5) |
| n (%) . | Overall (n = 139) . | Overweight/obese (n = 41) . | Hispanic (n = 40) . | Other non-Hispanic (n = 22) . |
|---|---|---|---|---|
| CAR construct | ||||
| CD19 | 50 (36.0) | 15 (36.6) | 18 (45.0) | 7 (31.8) |
| CD22 | 71 (51.1) | 19 (46.3) | 15 (37.5) | 12 (54.5) |
| CD19/22 | 18 (12.9) | 7 (17.1) | 7 (17.5) | 3 (13.6) |
| CRS ASTCT grade | ||||
| None | 33 (23.7) | 10 (24.4) | 12 (30.0) | 6 (27.3) |
| 1 | 47 (33.8) | 17 (41.5) | 9 (22.5) | 6 (27.3) |
| 2 | 34 (24.5) | 7 (17.1) | 7 (17.5) | 6 (27.3) |
| 3 | 20 (14.4) | 6 (14.6) | 10 (25.0) | 3 (13.6) |
| 4 | 5 (3.6)∗ | 1 (2.4) | 2 (5.0) | 1 (4.5) |
| Developed neurotoxicity | 29 (20.9) | 8 (19.5) | 9 (22.5) | 2 (9.1) |
| CR | ||||
| Yes | 94 (67.6) | 26 (63.4) | 25 (62.5) | 14 (63.6) |
| No | 44 (31.7) | 15 (36.6) | 15 (37.5) | 7 (31.8) |
| Not evaluable | 1 (0.7)∗ | 0 | 0 | 1 (4.5) |
One patient died of toxicity with grade 4 CRS and grade 5 capillary leak syndrome.